119 filings
Page 3 of 6
8-K
32qmf 9sfx
1 Jul 22
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
4:34pm
8-K
7fs mgn8ciefwhv
7 Jun 22
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
c1070g 9dcpzhcbj29c
20 May 22
Regulation FD Disclosure
4:12pm
8-K
binaejt4w yw67pz6t19
12 May 22
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
hyqzbtp
17 Mar 22
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
8:23am
8-K
zjyin fh7w7g
3 Mar 22
Entry into a Material Definitive Agreement
4:18pm
8-K
h9eekjy
9 Feb 22
Entry into a Material Definitive Agreement
4:10pm
8-K/A
qjgm4hau
26 Jan 22
Results of Operations and Financial Condition
7:56am
8-K
fv85vdaz
25 Jan 22
Results of Operations and Financial Condition
5:13pm
8-K
bhcy64ozzywpjxsdh
14 Jan 22
Entry into a Material Definitive Agreement
5:01pm
8-K
5g8mv8wsx axn
14 Jan 22
Termination of a Material Definitive Agreement
4:10pm
8-K
72vbfpvz
13 Dec 21
Regulation FD Disclosure
5:24pm
8-K
1f1s1cg3yv cx3
15 Nov 21
Regulation FD Disclosure
4:11pm
8-K
79loa85uc7vamk o3bg
12 Nov 21
Departure of Directors or Certain Officers
4:05pm
8-K
pqq22z 8uenwo2
5 Nov 21
Entry into a Material Definitive Agreement
5:27pm
8-K
g9e uxbzvgmrucpil
4 Nov 21
Results of Operations and Financial Condition
9:01am
8-K
47w1nfvucvux6gade
19 Oct 21
Departure of Directors or Certain Officers
4:56pm
8-K
rjqhlnrgat2 n1gz
10 Sep 21
Departure of Directors or Certain Officers
4:04pm
8-K
n7s7v ao496uhhz6grox
6 Aug 21
Regulation FD Disclosure
4:05pm
8-K
79i3f20dpb5hmj032q
3 Aug 21
X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter
8:12am